These Analysts Slash Their Forecasts On Haemonetics After Q1 Results

Group 1 - Haemonetics Corp reported quarterly earnings of $1.10 per share, exceeding the analyst consensus estimate of $1.02 per share [1] - The company reported quarterly sales of $321.394 million, surpassing the analyst consensus estimate of $305.115 million [1] - Haemonetics affirmed FY2026 adjusted EPS guidance of $4.70 to $5.00 [1] - Haemonetics shares closed at $55.63 on the day of the earnings announcement [1] Group 2 - JP Morgan analyst downgraded Haemonetics from Overweight to Neutral and lowered the price target from $85 to $62 [4] - Mizuho analyst maintained an Outperform rating on Haemonetics but lowered the price target from $90 to $70 [4] - Barrington Research analyst also maintained an Outperform rating while lowering the price target from $95 to $86 [4]